drugset / Trial / NCT01734694
Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients
RandomizedParallel-groupSingle-blindPrevention
Summary
For more than fifty years, vancomycin has been cited as a nephrotoxic agent. Reports of vancomycin induced kidney injury (a.k.a vancomycin induced nephrotoxicity or VIN), have waxed and waned throughout the years for various reasons. Recently, VIN has reemerged as a clinical concern. This may be due to various reasons, including new dosing recommendations as well as an increased prevalence of risk factors associated with vancomycin induced nephrotoxicity. This study aims to evaluate a strategy which attempts to reduce kidney damage from vancomycin use.
Timeline
- Start
- 2011-10
- Primary completion
- 2012-09
- Completion
- 2012-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ceftaroline | Other / unclassified | 200 mg | Intravenous |
| Comparator | Ceftaroline | Other / unclassified | 300 mg | Intravenous |
| Comparator | Ceftaroline | Other / unclassified | 400 mg | Intravenous |
| Comparator | Ceftaroline | Other / unclassified | 600 mg | Intravenous |
| Comparator | Daptomycin | Other / unclassified | 6 mg/kg | Intravenous |
| Comparator | Daptomycin | Other / unclassified | 10 mg/kg | Intravenous |
| Comparator | Linezolid | Other / unclassified | 600 mg | Intravenous |
| Comparator | Vancomycin | Other / unclassified | — | — |